Rasburicase biosimilar - Virchow Group

Drug Profile

Rasburicase biosimilar - Virchow Group

Alternative Names: Tuly

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Virchow Group
  • Class Antigouts; Oxidoreductases
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperuricaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 29 Aug 2012 Launched for Hyperuricaemia (In children, In adults) in India (IV) after August 2012
  • 29 Aug 2012 Launched for Hyperuricaemia (In children, Prevention, In adults) in India (IV) after August 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top